Cisplatin/etoposide Reactions 1680, p88 - 2 Dec 2017 Haematological disorders and hair loss: case report An adult woman in her 30’s [exact age at onset not stated] developed grade 4 neutropenia, grade 4 anaemia, grade 3 thrombocytopenia and grade 2 hair loss during treatment with cisplatin and etoposide [dosages, routes, time to reactions onsets and outcomes not stated]. The woman presented with colonic polyposis at the age of 36 and underwent a right hemicolectomy. After the operation, she was given a pathological diagnosis of mixed adenoneuroendocrine carcinoma pT1b N0 M0 stage I. She further developed multiple liver metastases and impaired liver function. She underwent chemotherapy with various drugs but her multiple liver metastases continued to grow larger and she also developed bone, ovary and lymph nodes metastases. Therefore, she was started on third-line chemotherapy with cisplatin plus etoposide. Subsequently, she developed grade 4 neutropenia, grade 4 anaemia, grade 3 thrombocytopenia and grade 2 hair loss. As a result of the ADR’s, she underwent 50% dose reduction of the drugs. The chemotherapy with cisplatin plus etoposide was continued for a further 4 courses but the metastatic lesions developed into progressive disease. As a result, amrubicin monotherapy was administered to the patient as the fourth-line chemotherapy. However, a clinical response was not observed and she died 20 months after the operation due to the metastatic mixed adenoneuroendocrine carcinoma. Author comment: "Therefore, the regimen was changed to cisplatin plus etoposide (EP) as the third-line chemotherapy. In the first course of the chemotherapy, the patient experienced Grade 4 neutropenia, Grade 4 anemia, Grade 3 thrombocytopenia, and Grade 2 hair loss." "[S]ome countries recommend EP regimen for the treatment. . . these regimens have a good response rate, many serious adverse events, particularly hematological toxicity, have been reported." Tagai N, et al. Favorable response of colonic mixed adenoneuroendocrine carcinoma to streptozocin monotherapy. International Cancer Conference Journal 6: 175-179, No. 4, Oct 2017. Available from: URL: s13691-017-0301-2 - Japan 803285114 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 Reactions Weekly Springer Journals


Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
Publisher site
See Article on Publisher Site


You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial